Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)

NCT02078973 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Nephropathy

Interventions

DRUG: 15 mg tolvaptan
DRUG: 30 mg tolvaptan
DRUG: 45 mg tolvaptan
DRUG: Placebo

Sponsor

Regional Hospital Holstebro

Collaborators

[object Object]